Premium
Lack of association between SLCO 1B1 polymorphisms and lipid‐lowering response to simvastatin therapy in Thai hypercholesterolaemic patients
Author(s) -
Kaewboonlert N.,
Thitisopee W.,
Sirintronsopon W.,
Porntadavity S.,
Jeenduang N.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12682
Subject(s) - simvastatin , medicine , pharmacology
Summary What is known SLCO 1B1 polymorphisms have been reported to affect the responses to statin therapy. However, the association of these polymorphisms and lipid‐lowering responses has been inconsistent. Objective To investigate the effect of SLCO 1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms on the lipid‐lowering response to simvastatin therapy in Thai hypercholesterolaemic patients. Methods Three hundred and 91 hypercholesterolaemic patients in Southern Thailand were enrolled and treated with simvastatin 20 or 40 mg per day. Among them, 191 and 200 patients were treated for 3 and 12 months, respectively. Serum lipids were measured before and after the treatment. SLCO 1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms were analysed using polymerase chain reaction‐high‐resolution melting ( PCR ‐ HRM ). Results The allele frequencies of the SLCO 1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms in Thai hypercholesterolaemic patients were 74.9%, 11.8% and 37.2%, respectively. After treatment with 20‐40 mg simvastatin daily for 3 and 12 months, TC , TG and LDL ‐C concentrations were significantly lower than at baseline ( P < .05). However, there was no a significant change in serum HDL ‐C after simvastatin treatment for 3 and 12 months ( P > .05). Moreover, there was no association between SLCO 1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms and lipid‐lowering response to 3 and 12 months of either 20 or 40 mg/day simvastatin treatment. What is new and conclusion SLCO 1B1 c.388A>G, c.521T>C and g.89595T>C polymorphisms may not be useful as genetic markers of lipid‐lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.